Literature DB >> 26294265

Why is it hard to terminate failing projects in pharmaceutical R&D?

Richard W Peck1, Dennis W Lendrem2, Iain Grant3, B Clare Lendrem2, John D Isaacs2.   

Abstract

'Quick-kill' strategies in pharmaceutical research and development aim to reduce late-stage attrition by bringing project termination decisions forward, to an earlier point in the process. How can the barriers to implementing such strategies be overcome?

Entities:  

Mesh：

Year:  2015        PMID： 26294265     DOI： 10.1038/nrd4725

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  5 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

Review 2.  Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development.

Authors:  Richard W Peck
Journal:  Drug Discov Today       Date:  2007-02-20       Impact factor: 7.851

Review 3.  A decade of innovation in pharmaceutical R&D: the Chorus model.

Authors:  Paul K Owens; Eyas Raddad; Jeffrey W Miller; John R Stille; Kenneth G Olovich; Neil V Smith; Rosie S Jones; Joel C Scherer
Journal:  Nat Rev Drug Discov       Date:  2014-12-15       Impact factor: 84.694

Review 4.  Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework.

Authors:  David Cook; Dearg Brown; Robert Alexander; Ruth March; Paul Morgan; Gemma Satterthwaite; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2014-05-16       Impact factor: 84.694

5.  Progression-seeking bias and rational optimism in research and development.

Authors:  Dennis W Lendrem; B Clare Lendrem; Richard W Peck; Stephen C Senn; Simon Day; John D Isaacs
Journal:  Nat Rev Drug Discov       Date:  2015-02-06       Impact factor: 84.694
  5 in total
  10 in total

1.  Organizational effectiveness: a key to R&D productivity.

Authors:  Peter Tollman; Valery Panier; Diana Dosik; Paul Biondi; Francis Cuss
Journal:  Nat Rev Drug Discov       Date:  2016-06-17       Impact factor: 84.694

Review 2.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 3.  Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Authors:  Hsin-Pei Shih; Xiaodan Zhang; Alex M Aronov
Journal:  Nat Rev Drug Discov       Date:  2017-10-27       Impact factor: 84.694

4.  Impact of a five-dimensional framework on R&D productivity at AstraZeneca.

Authors:  Paul Morgan; Dean G Brown; Simon Lennard; Mark J Anderton; J Carl Barrett; Ulf Eriksson; Mark Fidock; Bengt Hamrén; Anthony Johnson; Ruth E March; James Matcham; Jerome Mettetal; David J Nicholls; Stefan Platz; Steve Rees; Michael A Snowden; Menelas N Pangalos
Journal:  Nat Rev Drug Discov       Date:  2018-01-19       Impact factor: 84.694

Review 5.  Careers in nanomedicine and drug delivery.

Authors:  Elizabeth Nance
Journal:  Adv Drug Deliv Rev       Date:  2019-06-28       Impact factor: 15.470

Review 6.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

Review 7.  Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.

Authors:  Oktay Yildirim; Matthias Gottwald; Peter Schüler; Martin C Michel
Journal:  Front Pharmacol       Date:  2016-12-06       Impact factor: 5.810

8.  Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.

Authors:  Peter Y Yu; Heather L Gardner; Ryan Roberts; Hakan Cam; Seethalakshmi Hariharan; Ling Ren; Amy K LeBlanc; Hui Xiao; Jiayuh Lin; Denis C Guttridge; Xiaokui Mo; Chad E Bennett; Christopher C Coss; Yonghua Ling; Mitch A Phelps; Peter Houghton; Cheryl A London
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

9.  Take Care of the Fast-in-Human Study.

Authors:  E-J van Hoogdalem
Journal:  Clin Transl Sci       Date:  2017-01-10       Impact factor: 4.689

Review 10.  Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets.

Authors:  Suhas Vasaikar; Pooja Bhatia; Partap G Bhatia; Koon Chu Yaiw
Journal:  Biomedicines       Date:  2016-11-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.